High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Zentalis Pharmaceuticals
1 program
1
azenosertibPhase 2Small Molecule1 trial
Active Trials
NCT05128825RecruitingEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Zentalis Pharmaceuticalsazenosertib

Clinical Trials (1)

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start: Feb 2022Est. completion: Jun 2027
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space